BD成药企业绩增长新引擎,涉及先声药业、三生国健、荣昌生物等

动脉网
Feb 27

随着全球医药产业的迭代升级,中国创新药企如先声药业、三生国健和荣昌生物等正通过BD(业务发展)交易加速业绩增长。2025年,预计中国药企对外授权/许可/合作BD项目数量将达到165项,显著增加首付款与总金额。先声药业预计2025年收入约77-78亿元,同比增长16.0%-17.6%,主要得益于创新药收入和对外授权许可收入的增加。该公司已实现多个自研创新药项目的海外授权,潜在交易总金额累计超过46...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10